(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
4 days till quarter result
(amc 2024-05-08)
Expected move: +/- 4.43%
@ $27.40
发出时间: 14 Feb 2024 @ 22:30
回报率: 12.52%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -0.36 %
Live Chart Being Loaded With Signals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States...
Stats | |
---|---|
今日成交量 | 353 896 |
平均成交量 | 394 938 |
市值 | 1.69B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $0.390 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 1 541.50 |
ATR14 | $0.0330 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Bhatt Padmanabh P. | Buy | 14 491 | Common Stock |
2024-03-21 | Bhatt Padmanabh P. | Sell | 14 491 | Employee Stock Option (Right to Buy) |
2024-03-21 | Bhatt Padmanabh P. | Sell | 14 491 | Common Stock |
2024-03-20 | Bhatt Padmanabh P. | Sell | 400 | Employee Stock Option (Right to Buy) |
2024-03-20 | Bhatt Padmanabh P. | Buy | 400 | Common Stock |
INSIDER POWER |
---|
38.23 |
Last 100 transactions |
Buy: 802 366 | Sell: 356 762 |
音量 相关性
Supernus Pharmaceuticals 相关性 - 货币/商品
Supernus Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $607.52M |
毛利润: | $438.88M (72.24 %) |
EPS: | $0.0241 |
FY | 2023 |
营收: | $607.52M |
毛利润: | $438.88M (72.24 %) |
EPS: | $0.0241 |
FY | 2022 |
营收: | $667.24M |
毛利润: | $580.02M (86.93 %) |
EPS: | $1.130 |
FY | 2021 |
营收: | $579.78M |
毛利润: | $504.71M (87.05 %) |
EPS: | $1.010 |
Financial Reports:
No articles found.
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。